- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:46 | Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA's new chair | ||
| 17:46 | Pfizer stops selling hemophilia gene therapy, citing weak demand | ||
| 16:46 | Bluebird, at risk of default, agrees to take-private deal | ||
| Do | CDC vaccine meeting, set to be first since RFK Jr. sworn in, is postponed | ||
| Do | Device industry scrambles amid concern FDA layoffs will cause delays | ||
| Do | In FDA job cuts, experts see threat of far-reaching impact | ||
| Do | FTC case against PBMs can move forward, judge rules | ||
| Do | AstraZeneca deepens China presence with FibroGen deal | ||
| Do | BridgeBio's heart drug launch gets off to a fast start | ||
| Mi | Advamed CEO warns FDA job cuts put patients, industry at risk | ||
| Mi | Sanofi reaches consumer health deal; Supernus antidepressant fails study | ||
| Mi | FTC retains stricter merger guidelines under Trump | ||
| Mi | Recursion CEO launches pre-seed fund in response to NIH cuts | ||
| Di | Biogen buys rights to Stoke's rare epilepsy drug | ||
| Di | Solid says early data suggest 'differentiated' Duchenne gene therapy | ||
| Di | GSK's 5-in-1 meningococcal shot wins FDA approval | ||
| Di | Beyond copays: Redefining assistance for those with rare diseases and chronic conditions | ||
| 14.02. | 'It's not for the faint of heart.' How 3 CEOs took their biotechs public | ||
| 13.02. | Neumora shakes up its C-suite; Biogen cuts early-stage pipeline | ||
| 13.02. | A brain biotech launches with Roche's spare parts | ||
| 13.02. | RFK Jr. confirmed by Senate as health secretary | ||
| 13.02. | Sanofi to take $250M charge on study failure for E. Coli vaccine | ||
| 12.02. | Judge orders FDA, health agencies to restore removed webpages | ||
| 12.02. | New study offers hints of GLP-1 drugs' potential in curbing alcohol cravings | ||
| 12.02. | Biogen inks royalty deal to gain funding for lupus drug R&D |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
